ReP USP - Resultado da busca

Artigo de periodico
A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification (2025)
Scarisbrick, Julia J.; Quaglino, Pietro; Whittaker, Sean; Bagot, Martine; Guenova, Emmanuella; Papadavid, Evangelia; Prince, Henry Miles; Sanches Junior, Jose Antonio ; Miyashiro, Denis R.; Servitje, Octavio
Source: Blood. Unidade: FM
Subjects: ESTRATIFICAÇÃO SOCIAL, LINFOMA, PROGNÓSTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SCARISBRICK, Julia J. et al. A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification. Blood, v. 146, n. 14, p. 1687-1692, 2025Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/90827. Acesso em: 30 abr. 2026.
APA
Scarisbrick, J. J., Quaglino, P., Whittaker, S., Bagot, M., Guenova, E., Papadavid, E., et al. (2025). A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification. Blood, 146( 14), 1687-1692. doi:10.1182/blood.2025029628
NLM
Scarisbrick JJ, Quaglino P, Whittaker S, Bagot M, Guenova E, Papadavid E, Prince HM, Sanches Junior JA, Miyashiro DR, Servitje O. A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification [Internet]. Blood. 2025 ; 146( 14): 1687-1692.[citado 2026 abr. 30 ] Available from: https://observatorio.fm.usp.br/handle/OPI/90827
Vancouver
Scarisbrick JJ, Quaglino P, Whittaker S, Bagot M, Guenova E, Papadavid E, Prince HM, Sanches Junior JA, Miyashiro DR, Servitje O. A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification [Internet]. Blood. 2025 ; 146( 14): 1687-1692.[citado 2026 abr. 30 ] Available from: https://observatorio.fm.usp.br/handle/OPI/90827
Artigo de periodico
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC (2022)
Olsen, Elise A. ; Whittaker, Sean; Willemze, Rein ; Pinter-brown, Lauren; Foss, Francine ; Geskin, Larisa; Schwartz, Lawrence; Horwitz, Steven; Guitart, Joan; Zic, John
Source: Blood. Unidade: FM
Subjects: SINAIS E SINTOMAS, MANIFESTAÇÕES CUTÂNEAS, QUALIDADE DE VIDA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLSEN, Elise A. et al. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood, v. 140, n. 5, p. 419-437, 2022Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/50496. Acesso em: 30 abr. 2026.
APA
Olsen, E. A., Whittaker, S., Willemze, R., Pinter-brown, L., Foss, F., Geskin, L., et al. (2022). Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood, 140( 5), 419-437. doi:10.1182/blood.2021012057
NLM
Olsen EA, Whittaker S, Willemze R, Pinter-brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC [Internet]. Blood. 2022 ; 140( 5): 419-437.[citado 2026 abr. 30 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50496
Vancouver
Olsen EA, Whittaker S, Willemze R, Pinter-brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC [Internet]. Blood. 2022 ; 140( 5): 419-437.[citado 2026 abr. 30 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50496
Artigo de periodico
Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study (2020)
Dummer, Reinhard; Prince, Henry M; Whittaker, Sean; Horwitz, Steven M; Kim, Youn H; Scarisbrick, Julia; Quaglino, Pietro; Zinzani, Pier Luigi; Wolter, Pascal; Sanches Junior, Jose Antonio
Source: European journal of cancer. Unidade: FM
Subjects: ENSAIO CLÍNICO, LINFOMA, QUALIDADE DE VIDA, DOENÇAS DO SISTEMA NERVOSO PERIFÉRICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DUMMER, Reinhard et al. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. European journal of cancer, v. 133, p. 120-130, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.ejca.2020.04.010. Acesso em: 30 abr. 2026.
APA
Dummer, R., Prince, H. M., Whittaker, S., Horwitz, S. M., Kim, Y. H., Scarisbrick, J., et al. (2020). Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. European journal of cancer, 133, 120-130. doi:10.1016/j.ejca.2020.04.010
NLM
Dummer R, Prince HM, Whittaker S, Horwitz SM, Kim YH, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches Junior JA. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study [Internet]. European journal of cancer. 2020 ; 133 120-130.[citado 2026 abr. 30 ] Available from: https://doi.org/10.1016/j.ejca.2020.04.010
Vancouver
Dummer R, Prince HM, Whittaker S, Horwitz SM, Kim YH, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches Junior JA. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study [Internet]. European journal of cancer. 2020 ; 133 120-130.[citado 2026 abr. 30 ] Available from: https://doi.org/10.1016/j.ejca.2020.04.010
Artigo de periodico
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial (2017)
Prince, H. Miles; Kim, Youn H.; Horwitz, Steven M.; Dummer, Reinhard; Scarisbrick, Julia; Quaglino, Pietro; Zinzani, Pier Luigi; Wolter, Pascal; Sanches, Jose A.; Ortiz-Romero, Pablo L.; Akilov, Oleg E.; Geskin, Larisa; Trotman, Judith; Taylor, Kerry; Dalle, Stephane; Weichenthal, Michael; Walewski, Jan; Fisher, David; Dréno, Brigitte; Stadler, Rudolf; Feldman, Tatyana; MKuzel, Timothy; Wang, Yinghui; Palanca-Wessels, Maria Corinna; Zagadailov, Erin; Trepicchio, William L; Zhang, Wenwen; Lin, Hui-Min; Liu, Yi; Huebner, Dirk; Little, Meredith; Whittaker, Sean; Duvic, Madeleine
Source: Lancet. Unidade: FM
Subjects: LINFOMA, ESTRATÉGIAS TERAPÊUTICAS, ANTINEOPLÁSICOS, MANIFESTAÇÕES CUTÂNEAS, PROGNÓSTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PRINCE, H. Miles et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet, v. 390, n. 10094, p. 555-566, 2017Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(17)31266-7. Acesso em: 30 abr. 2026.
APA
Prince, H. M., Kim, Y. H., Horwitz, S. M., Dummer, R., Scarisbrick, J., Quaglino, P., et al. (2017). Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet, 390( 10094), 555-566. doi:10.1016/S0140-6736(17)31266-7
NLM
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, MKuzel T, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin H-M, Liu Y, Huebner D, Little M, Whittaker S, Duvic M. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial [Internet]. Lancet. 2017 ; 390( 10094): 555-566.[citado 2026 abr. 30 ] Available from: https://doi.org/10.1016/S0140-6736(17)31266-7
Vancouver
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, MKuzel T, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin H-M, Liu Y, Huebner D, Little M, Whittaker S, Duvic M. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial [Internet]. Lancet. 2017 ; 390( 10094): 555-566.[citado 2026 abr. 30 ] Available from: https://doi.org/10.1016/S0140-6736(17)31266-7
Artigo de periodico
Clinical end points and response criteria in mycosis fungoides and sézary syndrome: A consensus statement of the international society for cutaneous lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the European Organisation for Research and Treatment of Cancer (2011)
Olsen, Elise A; Whittaker, Sean; Kim, Youn H; Duvic, Madeleine; Prince, H Miles; Lessin, Stuart R; Wood, Gary S; Willemze, Rein; Demierre, Marie-France; Pimpinelli, Nicola; Bernengo, Maria Grazia; Ortiz-Romero, Pablo L; Bagot, Martine; Estrach, Teresa; Guitart, Joan; Knobler, Robert; Sanches Júnior, José Antonio; Iwatsuki, Keiji; Sugaya, Makoto; Dummer, Reinhard; Pittelkow, Mark; Hoppe, Richard; Parker, Sareeta; Geskin, Larisa; Pinter-Brown, Lauren; Girardi, Michael; Burg, Günter; Ranki, Annamari; Vermeer, Maartan; Horwitz, Steven; Heald, Peter; Rosen, Steve; Cerroni, Lorenzo; Dreno, Brigette; Vonderheid, Eric C
Source: Journal of clinical oncology. Unidade: FM
Subjects: MICOSES (DIAGNÓSTICO), FUNGOS, LINFOMA (TERAPIA), MANIFESTAÇÕES CUTÂNEAS, PROGNÓSTICO, BIÓPSIA, LINFEDEMA (ETIOLOGIA), HEMORRAGIA (ETIOLOGIA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLSEN, Elise A et al. Clinical end points and response criteria in mycosis fungoides and sézary syndrome: A consensus statement of the international society for cutaneous lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the European Organisation for Research and Treatment of Cancer. Journal of clinical oncology, v. 29, n. 18, p. 2598-2607, 2011Tradução . . Disponível em: https://doi.org/10.1200/JCO.2010.32.0630. Acesso em: 30 abr. 2026.
APA
Olsen, E. A., Whittaker, S., Kim, Y. H., Duvic, M., Prince, H. M., Lessin, S. R., et al. (2011). Clinical end points and response criteria in mycosis fungoides and sézary syndrome: A consensus statement of the international society for cutaneous lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the European Organisation for Research and Treatment of Cancer. Journal of clinical oncology, 29( 18), 2598-2607. doi:10.1200/JCO.2010.32.0630
NLM
Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre M-F, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches Júnior JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC. Clinical end points and response criteria in mycosis fungoides and sézary syndrome: A consensus statement of the international society for cutaneous lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the European Organisation for Research and Treatment of Cancer [Internet]. Journal of clinical oncology. 2011 ; 29( 18): 2598-2607.[citado 2026 abr. 30 ] Available from: https://doi.org/10.1200/JCO.2010.32.0630
Vancouver
Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre M-F, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches Júnior JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC. Clinical end points and response criteria in mycosis fungoides and sézary syndrome: A consensus statement of the international society for cutaneous lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the European Organisation for Research and Treatment of Cancer [Internet]. Journal of clinical oncology. 2011 ; 29( 18): 2598-2607.[citado 2026 abr. 30 ] Available from: https://doi.org/10.1200/JCO.2010.32.0630

USP Schools

ReP

Filtros

Authors

Subjects

Indexado em

Non normalized affiliation